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Abstract: Factor XIII (FXIII) is a transglutaminase that promotes thrombus stability by cross-linking
fibrin. The cellular form, a homodimer of the A subunits, denoted FXIII-A, lacks a classical signal
peptide for its release; however, we have shown that it is exposed on activated platelets. Here we
addressed whether monocytes expose intracellular FXIII-A in response to stimuli. Using flow
cytometry, we demonstrate that FXIII-A antigen and activity are up-regulated on human monocytes
in response to stimulation by IL-4 and IL-10. Higher basal levels of the FXIII-A antigen were
noted on the membrane of the monocytic cell line THP-1, but activity was significantly enhanced
following stimulation with IL-4 and IL-10. In contrast, treatment with lipopolysaccharide did not
upregulate exposure of FXIII-A in THP-1 cells. Quantification of the FXIII-A activity revealed a
significant increase in THP-1 cells in total cell lysates following stimulation with IL-4 and IL-10.
Following fractionation, the largest pool of FXIII-A was membrane associated. Monocytes were
actively incorporated into the fibrin mesh of model thrombi. We found that stimulation of monocytes
and THP-1 cells with IL-4 and IL-10 stabilized FXIII-depleted thrombi against fibrinolytic degradation,
via a transglutaminase-dependent mechanism. Our data suggest that monocyte-derived FXIII-A
externalized in response to stimuli participates in thrombus stabilization.
Keywords: factor XIII-A; fibrinolysis; monocytes; thrombi; transglutaminase; cross-linking
1. Introduction
The protransglutaminase factor XIII circulates in plasma (pFXIII) as a tetramer of two
A subunits and two carrier B subunits [1]. It is activated at the final stages of the clotting
reaction via the concerted action of thrombin and Ca2+. The resulting active enzyme,
pFXIIIa, catalyzes an acyl transfer reaction between lysine and glutamine amino acids
forming intra- or inter-molecular cross-links [1]. The primary substrates for pFXIIIa are
fibrin and α2antiplasmin (α2AP), cross-linking of which increases the stability of a fibrin
clot against mechanical stress and fibrinolytic degradation, respectively [2]. A deficiency
in FXIII manifests as a severe bleeding diathesis with patients requiring regular FXIII
replacement therapy. In addition to its essential role in hemostasis, pFXIII functions
in several other related biological processes, such as the maintenance of pregnancy [1],
wound healing and angiogenesis [3].
The cellular form of FXIII is a homodimer of the A-subunits, termed FXIII-A that
is localized to a wide variety of cells, including platelets, megakaryocytes, monocytes,
and tissue macrophages, dendritic cells, chondrocytes, osteoblasts and preadipocytes
(recently reviewed by [4]). Cellular FXIII-A is non-proteolytically activated by modest
increases in intracellular Ca2+ concentrations [5,6]. The mechanism of FXIII-A release
from these cells remains an enigma, as it lacks a signal sequence and is absent from the
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endoplasmic reticulum (ER)-Golgi secretory pathway in nucleated cells [7]. However, FXIII-
A in monocyte-macrophages is reportedly directed to the plasma membrane in association
with Golgi vesicles [8] indicating secretion follows an alternative pathway.
Platelets were hypothesized to be the source of the FXIII-A subunit in plasma [9,10]
as they contain an abundance of FXIII-A in their cytoplasm. However, this was ruled out,
as in thrombocytopenic mice plasma levels of FXIII-A were within the normal range [8].
Tissue-specific mouse knockouts of FXIII-A pinpoint resident tissue macrophages as the
cellular source of plasma FXIII-A [11]. Nonetheless, our laboratory has demonstrated that
activated platelets expose functional FXIII-A which is capable of crosslinking α2AP and
fibrin, therefore stabilizing thrombi against degradation [12]. The platelet pool of FXIII-A
may be functional in the microenvironment of the thrombus where solute transport of the
plasma pool is low [13].
There is mounting evidence that venous thrombosis is an inflammatory condition and
in line with this, acute infections predispose to the condition [14]. Monocytes have been
proposed to function in the initiation and propagation of venous thrombosis [15] and are
actively recruited to thrombi in a cytokine-dependent manner [16]. Monocytes are a rich
source of FXIII-A [17]; however, as it is not classically secreted it is unclear whether this
transglutaminase could participate in stabilization of venous thrombi. In this study we
investigate whether FXIII-A is externalized on the surface of monocytes and if this cellular
form can function in extracellular cross-linking reactions. We show for the first time that
active FXIII-A is exposed on the surface of IL-4- and IL-10-activated monocytes and that
this cellular pool of transglutaminase stabilizes thrombi against fibrinolytic degradation.
2. Results
2.1. FXIII-A Antigen and Activity Are Exposed on the Surface of Human Monocytes and
THP-1 Cells
FXIII-A is synthesized by monocytes [9,18] but lacks a classical secretion signal and
has been assumed to exert only intracellular crosslinking activity. We examined whether
FXIII-A is exposed on the surface of human monocytes or THP-1 cells in response to specific
stimuli using flow cytometry and confocal microscopy. Human-derived monocytes or
THP-1 cells were left unstimulated or were stimulated with IL-4, IL-10 or LPS, as classical
monocyte-activating stimuli [19].
A significant increase was observed in the number of IL-10-stimulated monocytes
exposing the FXIII-A antigen relative to unstimulated cells (21.2 ± 3.4% vs. 7.9 ± 2.1%
p < 0.05; Figure 1A). Increased numbers of monocytes exposing the FXIII-A antigen were
also observed post-stimulation with IL-4 and LPS (Figure 1A) but did not reach statistical
significance. Median fluorescence intensity (MFI) was also significantly increased following
stimulation with IL-10 compared to resting cells (613 ± 119 % vs. 340 ± 75% p < 0.05;
Figure 1A). FXIII-A activity, detected using the TAMRA substrate, was significantly in-
creased with IL-4 and IL-10 compared to resting cells (p < 0.05; Figure 1A); however,
the MFI was significantly increased with IL-10 only (p < 0.05; Figure 1A). These data indi-
cate that basal levels of the FXIII-A antigen on monocytes were increased following stimuli,
particularly IL-10, but that functional FXIII-A was significantly elevated post-stimulation.
The basal level of the FXIII-A antigen on the surface of resting THP-1 cells was almost
10-fold higher than that on human-derived monocytes (73.6 ± 12.7% vs. 7.9 ± 2.1%).
Stimulation of THP-1 cells with IL-4 and IL-10 had a negligible impact on the number
of cells positive for the FXIII-A antigen or the MFI (Figure 1B). In contrast there was a
dramatic increase in THP-1 cells positive for FXIII-A activity post-stimulation with IL-4,
IL-10 and LPS compared to unstimulated cells (p < 0.001; Figure 1B). However, the MFI was
only significantly increased following stimulation with IL-4 and IL-10 (p < 0.01; p < 0.05;
respectively; Figure 1B). These data indicate that despite expression of high basal levels
of FXIII-A on THP-1 cells, this pool is largely inactive. Stimulation with IL-4 and Il-10
significantly increased the pool of active FXIII-A on the surface of THP-1.
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Figure 1. Active FXIII-A is exposed on the surface of isolated human monocytes and THP-1 cells. (A) Isolated human 
monocytes or (B) THP-1 cells were left unstimulated or stimulated with IL-4 (20 ng/mL), IL-10 (20 ng/mL) or LPS (100 ng/mL) for 24 h prior 
to staining using FITC labelled anti-FXIII-A antibody or TAMRA donor FXIII-A substrate for detection of functional 
activity. Samples were then analyzed using an LSR II flow cytometer. Data are expressed as a percentage of FXIII-A 
positive monocytes and median fluorescence intensity (MFI) values as the mean ± SEM, n = 3. * p < 0.05; ** p < 0.01; *** p < 
0.001 vs. resting cells. 
Fluorescence confocal microscopy was performed on live, non-permeabilized cells 
using a specific antibody to FXIII-A. We found that FXIII-A antigen and activity were 
expressed on the external membrane of human-derived monocytes (Figure 2A) and were 
increased post-stimulation. The increased signal was particularly evident with IL-10 
Figure 1. Active FXIII-A is exposed on the surface of isolated human monocytes and THP-1 cells. (A) Isolated human
monocytes or (B) THP-1 cells were left unstimulated or stimulated with IL-4 (20 ng/mL), IL-10 (20 ng/mL) or LPS
(100 ng/mL) for 24 h prior to staining using FITC labelled anti-FXIII-A antibody or TAMRA donor FXIII-A substrate
for detection of functional activity. Samples were then analyzed using an LSR II flow cytometer. Data are expressed as
a percentage of FXIII-A positive monocytes and median fluorescence intensity (MFI) values as the mean ± SEM, n = 3.
* p < 0.05; ** p < 0.01; *** p < 0.001 vs. resting cells.
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Fluorescence confocal microscopy was performed on live, non-permeabilized cells
using a specific antibody to FXIII-A. We found that FXIII-A antigen and activity were
expressed on the external membrane of human-derived monocytes (Figure 2A) and were
increased post-stimulation. The increased signal was particularly evident with IL-10
stimulation, in line with the flow cytometry data. The FXIII-A antigen and activity were
evident on THP-1 cells with an increase evident post-stimulation with IL-4 and IL-10
(Figure 2B). The pattern of staining with IL-10 appeared more diffuse across the THP-1 cells
with changes in FXIII-A activity, in agreement with the flow cytometry data (Figure 1B).
We investigated a possible synergistic effect of co-stimulation with IL-4 and IL-10 on
FXIII-A exposure in THP-1 cells but found no evidence of increased signals over single
stimulation (data not shown). Interestingly, stimulation of THP-1 cells with LPS resulted
in a different distribution of FXIII-A, evident as a distinct punctate pattern around the
periphery of the cells. FXIII-A activity was observed in vesicular compartments within
the THP-1 cells. These images suggest that FXIII-A is perhaps differently expressed on
THP-1 cells in response to different stimuli. Interestingly, increasing the stimulation time
of THP-1 cells to 48 h resulted in a loss of the FXIII-A signal in cells stimulated with LPS,
again suggestive of internalization and degradation of FXIII-A. In contrast, a stronger
signal was noted with IL-4 and IL-10 following 48 h stimulation (Figure S1).
2.2. FXIII-A Activity in IL-4- or IL-10-Activated THP-1 Cells Primarily Localized to the
Cell Membrane
Changes in FXIII-A activity following stimulation of THP-1 cells with IL-4, IL-10
and LPS were quantified by an in-house activity assay. Stimulation with IL-4 and IL-10
(1.58 ± 0.20; 2.98 ± 0.10 IU/mL; p < 0.001; respectively) significantly increased FXIII-A
activity in the total cell lysate compared to unstimulated cells (0.24 ± 0.03; Figure 3A).
However, stimulation with LPS did not augment FXIII-A activity, in line with the flow
cytometry data. Fractionation of the cells revealed that following stimulation of THP-
1 with IL-4 and IL-10, the largest pool of active FXIII-A was located in the membrane
(1.00 ± 0.12 IU/mL; p < 0.01; 1.68 ± 0.27 IU/mL; p < 0.001; respectively; Figure 3D). Active
FXIII-A was also detected in the cytoplasm fraction of the cells post-stimulation with
IL-4 and IL-10 with a smaller pool within the supernatant. LPS stimulation did not drive
up-regulation of FXIII-A in the supernatant, cytoplasm, or membrane fraction. These data
indicate that stimulation of THP-1 cells with IL-4 and IL-10 enriches the intracellular pools
of the transglutaminase which is directed toward the membrane.
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Figure 2. Distribution of FXIII-A on the surface of isolated human monocytes or THP-1 cells. (A) Isolated human 
monocytes or (B) THP-1 cells were left unstimulated or stimulated with IL-4 (20 ng/mL), IL-10 (20 ng/mL) or LPS (100 ng/mL) for 24 h. Live 
cells were stained using FITC labelled anti-FXIII-A antibody or TAMRA donor FXIII-A substrate for detection of activity. 
Cells were imaged using a LSM880 confocal microscope using a 63 × 1.40 oil immersion. Images are representative of n ≥ 3; 
scale bar 10 μm (A) or 5 μm (B). 
Figure 2. Distribution of FXIII-A on the surface of isolated human monocytes or THP-1 cells. (A) Isolated human monocytes
or (B) THP-1 cells were left unstimulated or stimulated with IL-4 (20 ng/mL), IL-10 (20 ng/mL) or LPS (100 ng/mL) for
24 h. Live cells were stained using FITC labelled anti-FXIII-A antibody or TAMRA donor FXIII-A substrate for detection of
activity. Cells were imaged using a LSM880 confocal microscope using a 63 × 1.40 oil immersion. Images are representative
of n ≥ 3; scale bar 10 µm (A) or 5 µm (B).
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Figure 3. Activation of THP-1 cells by IL-4 or IL-10 increases FXIII-A activity which is primarily 
associated with the cell cytoplasm and membrane fractions. THP-1 cells (6 × 10⁶ cells/mL) left 
unstimulated or stimulated with 20 ng/mL IL-4, 20 ng/mL IL-10 or 100 ng/mL LPS for 24 h. The 
supernatant was collected by centrifugation of cells at 2500× g for 5 min. The cells were washed 
twice in cold sterile PBS and centrifuged at 2500× g for 5 min before being resuspended in RIPA 
buffer. The lysate was centrifuged at 14,000× g for 15 min and the supernatant was collected as 
cytoplasm fractions and the precipitate was resuspended in RIPA buffer as cell membrane 
fractions. FXIII-A activity (IU/mL) was measured in (A) total cell lysate of unstimulated or IL-4, IL-
10 or LPS-stimulated cells and cell fractions (B) supernatant, (C) cytoplasm or (D) membrane. * p < 
0.05; ** p < 0.01; *** p < 0.001 vs. unstimulated THP-1 cells. Data are expressed as the mean with 
standard error of the mean SEM (n = 3). 
2.3. Monocytes Are Incorporated in Thrombi 
For externalized monocyte-derived FXIII-A to have a functional impact on clot 
stability, these cells would need to be incorporated during thrombus formation or have 
the capacity to invade mature thrombi. We investigated incorporation of the monocytic 
cell line THP-1 into thrombi under shear stress, using the Chandler model thrombus 
system, which has previously been used to reveal the role of FXIII-mediated cross-linking 
in resistance to fibrinolysis [20,21]. Thrombi were formed with FXIII-/--deficient plasma in 
the presence of THP-1 cells. Immunohistochemical analysis revealed staining for FXIII-A 
in areas of the thrombi immediately adjacent to cells and in fibrin-rich areas (Figure 4). 
These results indicate that monocytes act as a vehicle to deliver FXIII-A into thrombi, 
therefore allowing this transglutaminase to stabilize the forming thrombus against 
premature fibrinolytic degradation.  
Figure 3. Activation of THP-1 cells by IL-4 or IL-10 increases FXIII-A activity which is primarily
associated with the cell cytoplasm and membrane fractions. THP-1 cells (6 × 106 cells/mL) left
unstimulated or stimulated with 20 ng/mL IL-4, 20 ng/mL IL-10 or 100 ng/mL LPS for 24 h.
The supernatant was collected by centrifugation of cells at 2500× g for 5 min. The cells were ashed
twice in cold sterile PBS and centrifuge at 2500 g for 5 min before being res s e e i I
buffer. The lysate was centrifuged at 14,000× g for 15 min and the supernatant was collected as
cytoplasm fracti recipitate was resuspended in RIPA buffer as cell me brane fractions.
FXIII-A activity (IU/mL) was measured in (A) total cell lysate of uns imulated or IL-4, IL-10 or
LPS-stimulated cells and cell fractions (B) supernatant, (C) cytoplasm or (D) membran . * p < 0.05;
** p < 0.01; *** p < 0.001 vs. unstimulated THP-1 cells. Data are expressed as the mean with standard
error of the mean SEM (n = 3).
2.3. Monocytes Are Incorporated in Thrombi
For externalized monocyte-derived FXIII-A to have a functional impact on clot sta-
bility, these cells would need to be incorporated during thrombus formation or have the
capacity to invade mature thrombi. We investigated incorporation of the monocytic cell
line THP-1 into thrombi under shear stress, using the Chandler model thrombus system,
which has previously been used to reveal the role of FXIII-mediated cross-linking in re-
sistance to fibrinolysis [20,21]. Thrombi were formed with FXIII-/--deficient plasma in
the presence of THP-1 cells. Immunohistochemical analysis revealed staining for FXIII-A
in areas of the thrombi immediately adjacent to cells and in fibrin-rich areas (Figure 4).
These results indicate that monocytes act as a vehicle to deliver FXIII-A into thrombi, there-
fore allowing this transgluta inase to t bilize the forming thrombus against premature
fibrin lytic degradation.




Figure 4. Monocytes are incorporated into forming thrombi. Model thrombi were formed under arterial shear rates with FXIII–
/– plasma in the presence of THP-1 cells. Thrombi were fixed in 10% formalin and wax embedded prior to sectioning. 
Sections were deparaffinized and stained with a polyclonal rabbit anti-fibrin(ogen) (top panel) or anti-FXIII-A (bottom 
panel) antibodies (brown) and counterstained with Mayer’s haematoxylin (blue) for detection of the nuclei of THP-1 cells. 
Imaged using 5× magnification. Cell clusters were detected in certain locations (inset and as indicated by arrows). Scale 
bar = 100 μm. 
2.4. Monocytes Enhance Thrombus Stability in a Transglutaminase-Dependent Manner 
We have previously shown that FXIII-A exposed on the surface of activated platelets 
stabilizes thrombi against fibrinolytic resistance [12]. Here we show that human-derived 
monocytes and the monocytic cell line, THP-1, expose functional FXIII-A and are 
incorporated into thrombi under shear conditions. We next investigated whether they 
could augment thrombus stability. Depletion of plasma FXIII or inhibition of plasma 
FXIII-A with a TG inhibitor enhanced tPA-mediated lysis >10-fold (Figure 5A, p <0.001), 
consistent with our previous observations [20]. Inclusion of THP-1 cells in model thrombi 
formed from FXIII deficient plasma did not significantly change the stability against tPA-
mediated degradation (Figure 5A). In contrast, THP-1 cells stimulated with IL-4 or IL-10 
enhanced thrombus stability 1.7-fold (Figure 5B; p < 0.001). These results are consistent 
with the observed increase in FXIII-A antigen and activity on THP-1 cells. LPS-stimulated 
THP-1 cells were unable to stabilize thrombi (Figure 5C), reflecting the reduction of the 
FXIII-A antigen and activity on these cells.  
We next analyzed human-derived monocytes and found unstimulated cells induced 
a small but significant effect on the stability of thrombi formed from FXIII-deficient 
thrombi (Figure 5D; p < 0.005). IL-4 and IL-10 stimulation of human-derived monocytes 
enhanced thrombus stability against tPA-mediated degradation approximately 2-fold 
compared to FXIII deficient thrombi (Figure 5E; p < 0.001). In marked contrast, LPS 
stimulation of monocytes did not significantly impact thrombus stability (Figure 5F). 
These functional data are in line with the confocal images demonstrating less FXIII-A 
antigen and activity on unstimulated and LPS-stimulated monocytes.  
Figure 4. Monocytes are incorporated into forming thrombi. Model thrombi were formed und arterial shear rates with
FXIII–/– plasma in the presence of THP-1 cells. Thrombi were fixed in 10% formalin and wax e bedded prior to sectioning.
Sections were deparaffinized and stained with a polyclonal rabbit anti-fibrin(ogen) (top panel) or anti-FXIII-A (bottom
panel) antibodies (brown) and counterstained with Mayer’s haematoxylin (blue) for detection of the nuclei of THP-1
cells. Imaged using 5× magnification. Cell clusters were detected in certain locations (inset and as indicated by arrows).
Scale bar = 100 µm.
2.4. Monocytes Enhance i a Transglutaminase-Dependent Manner
We have r i l t III- exposed on the surface of activated platel ts
stabilizes thro bi i st fi ri l tic resistance [12]. Here we show that human-derived
monocytes and the monocytic cell line, THP-1, expose functional FXIII-A and are incor-
porated into thrombi under shear conditions. We next investigated whether they could
augment thrombus stability. Depletion of plasma FXIII or inhibition of plasma FXIII-A
with a TG inhibitor enhanced tPA-mediated lysis >10-fold (Figure 5A, p <0.001), consistent
with our previous observations [20]. Inclusion of THP-1 cells in model thrombi formed
from FXIII deficient plasma did not significantly change the stability against tPA-mediated
degradation (Figure 5A). In contrast, THP-1 cells stimulated with IL-4 or IL-10 enhanced
thrombus stability 1.7-fold (Figure 5B; p < 0.001). These results are consistent with the
observed increase in FXIII-A antigen and activity on THP-1 cells. LPS-stimulated THP-1
cells were unable to stabilize thrombi (Figure 5C), reflecting the reduction of the FXIII-A
antigen and activity on these cells.
We next analyzed human-derived monocytes and found unstimulated cells induced a
small but significant effect on the stability of thrombi formed from FXIII-deficient thrombi
(Figure 5D; p < 0.005). IL-4 and IL-10 stimulation of human-derived monocytes enhanced
thrombus stability against tPA-mediate degradation approximately 2-fold compared to
FXIII deficient thrombi (Figure 5E; p < 0.001). In marked contrast, LPS sti ulation of
monocytes did not significantly impact thrombus stability (Figure 5F). These functional
data are i line with the confocal images demonstrating less FXIII-A antigen and activity
on unstimulated and LPS-stimulated monocytes.
Int. J. Mol. Sci. 2021, 22, 6591 8 of 15




Figure 5. FXIII-A deficient thrombi are stabilized by THP-1 cells and human-derived monocytes stimulated with IL-4 and 
IL-10. Model thrombi were formed with pooled normal plasma (PNP) or FXIII-/- plasma in the presence of and FITC-
labelled fibrinogen under arterial shear rates. Lysis was subsequently induced by tPA (1 μg/mL) and monitored for 4 h. 
Fluorescence release is directly proportional to the degree of fibrinolysis. PNP thrombi were formed in the absence (grey) 
and presence (orange) of the TG inhibitor and FXIII-/- thrombi formed without (black) and with (blue) 3 × 105/mL (A) THP-
1 cells or (D) human-derived monocytes. *** p < 0.001 vs. PNP; # p < 0.05 vs. FXIII-/--deficient thrombi. (B) THP-1 cells or 
(E) human-derived monocytes were stimulated for 24 h with IL-4 (pink) or IL-10 (purple) prior to thrombus formation # p 
< 0.05 or *** p < 0.001 vs. FXIII-/--deficient thrombi (C) THP-1 cells or (F) human-derived monocytes were stimulated for 24 
h with LPS (green) before addition to thrombi. # p < 0.05 vs. FXIII-/--deficient thrombi. Values represent the mean ± SEM, 
n = 4. 
To establish whether the stabilizing effect of cells on thrombi is mediated by FXIII-A, 
a TG inhibitor was included during thrombus formation. The presence of the TG inhibitor 
abrogated the stabilizing effect of IL-4-stimulated THP-1 cells (p < 0.005; Figure 6), 
confirming that thrombus resistance is conferred by increased FXIII-A-mediated cross-
linking. 
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Figure 6. Stabilization of thrombi with IL-4-stimulated THP-1 cells occurs in a transglutaminase-
dependent manner. Model thrombi were formed with PNP or FXIII-/- plasma and FITC-labelled
fibrinogen under arterial shear rates, and ly is was subsequently induced by tPA (1 µg/ L). Fluo-
resce ce release is directly proportional to the degree of fibrinolysis. FXIII-/- thrombi were formed
without (black) and with (pink) 3 × 105/mL IL-4 stimulated THP-1 cells in the absence (closed
symbols) and presence (open symbols) of the TG inhibitor. Values represent the mean ± SEM, n = 4,
** p < 0.005 vs. IL-4 stimulated THP-1 cells.
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3. Discussion
Inflammatory cells are now recognized to play a key role in thrombus initiation and
propagation [15]. FXIII-A is abundant in monocytes [17] but its potential extracellular role
in thrombus formation and stabilization has not been examined. Here we show for the first
time that FXIII-A is externalized on the monocyte surface in response to different stimuli.
Externalization of this transglutaminase is associated with an increase in thrombus stability,
indicating that it is functional in performing extracellular cross-linking reactions. Indeed,
staining of FXIII-A was noted within the fibrin mesh of thrombi formed in the presence
of monocytes. These data suggest that FXIII-A is constitutively expressed by monocytes
and externalized onto the outer leaflet of the membrane, despite the lack of a classical ER
release signal and its exclusion from the ER-Golgi pathway in nucleated cells [7].
Resting human-derived monocytes demonstrated surface exposure of FXIII-A that
was largely inactive in nature. Stimulation of human-derived monocytes with IL-10 and IL-
4 increased exposure of FXIII-A which was accompanied by a significant increase in FXIII-A
activity and extracellular crosslinking activity. In contrast, stimulation with LPS increased
exposure of FXIII-A, as detected by flow cytometry, but had little functional impact on
thrombus stability over unstimulated monocytes. In THP-1 cells, surface expression of
FXIII-A was around 10-fold higher than human-derived monocytes but was largely inactive.
IL-4 and IL-10 stimulation significantly increased FXIII-A activity on the surface of THP-1
cells and in line with this, enhanced thrombus stability. LPS did not alter THP-1 surface
expression of FXIII-A to the same degree as human-derived monocytes. The differences
in the response of primary monocytes and the monocytic cell line to LPS are documented
in the literature and arise due to low levels of CD14 expressed on the immortalized cell
line compared to primary cells [22]. Activity assays on THP-1 cells echoed the flow
cytometry and confocal data and revealed that FXIII-A is largely associated with the
membrane fraction of cells post-stimulation with IL-4 and IL-10. Dual stimulation with
IL-4 and IL-10 did not result in a synergistic increase in externalization of FXIII-A on THP-
1 cells, suggesting that these activators function through the same pathway to increase
externalization of FXIII-A. The number of signaling pathways shared between IL-4 and IL-
10 receptors are limited [23], and this knowledge could potentially pinpoint the signaling
pathway responsible for externalization of FXIII-A. Exposure of FXIII-A on monocytic cells
was time-dependent, with an increase in FXIII-A exposure with IL-4 or IL-10 stimulation
over time. In contrast, prolonged stimulation with LPS resulted in a loss of FXIII-A signal,
potentially related to internalization. These data are consistent with a previous report
showing a time-dependent increase in FXIII-A exposure in monocytes stimulated with
IL-4 [24]. Indeed, Törőcsik et. al. suggested that the expression of FXIII-A is an intracellular
marker of IL-4-activated macrophages [24] and monocyte-derived dendritic cells also
express FXIII-A in response to IL-4 [25]. Monocytes are highly sensitive to IL-10, with the
antiflammatory cytokine playing a key role in regulating innate and adaptive immune
responses [26]. However, to the best of our knowledge this is the first report that IL-10 can
up-regulate monocyte expression of FXIII-A which may function in these processes.
Expression of FXIII-A was analyzed on non-permeabilized monocytic cells, but FXIII-
A and TAMRA staining was observed in a punctuated pattern on LPS-stimulated cells.
No such staining was observed in the controls, suggesting this was not accounted for
by autofluorescence. Consistent with this, macrophages have been shown to accumulate
FXIII-A in pseudopods and cytoplasmic vacuoles [27]. LPS is known to induce vacuolar
structures in macrophages that are derived from the plasma membrane and endoplasmic
reticulum [28]. In LPS-activated macrophage macropinocytosis occurs constitutively and
upon particle phagocytosis, leading to intracellular vacuole formation [29]. Our observa-
tions suggest that a similar mechanism of pinocytosis occurs in monocytes in response to
LPS stimulation. Interestingly, FXIII-A itself has been implicated in Fcγ-receptor-mediated
phagocytosis, with monocytes from FXIII-deficient patients demonstrating decreased
phagocytosis compared to healthy controls [30].
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Cellular FXIII-A has primarily been considered to function in cytoskeletal remodel-
ing as molecules such as myosin [31], actin [32] and vinculin [33] serve as substrates for
intracellular FXIII-A. We have previously described a role for platelet-derived FXIII-A in
stabilizing thrombi [12]. Here we analyzed the potential function of monocyte-derived
FXIII-A in thrombus stability and found that cellular FXIII-A of monocyte origin could
act to promote thrombus stability against fibrinolytic degradation. Monocytes were de-
tected in thrombi formed from FXIII-deficient plasma under a physiological flow rate,
thus indicating incorporation of cells into forming thrombi and consistent with the other
reported roles of monocytes in thrombus initiation and propagation [15]. Addition of IL-4
and IL-10 activated monocytes significantly increased the stability of thrombi formed from
FXIII-deficient plasma, whereas inclusion of a transglutaminase inhibitor abrogated the
stabilizing effect of IL-4-stimulated monocytes in FXIII-deficient thrombi. In contrast, LPS-
stimulated monocytes have no additional impact on thrombus stability over resting cells,
most likely due to reduced exposure of functional FXIII-A. The 1,3-dimethy-2-imidazolium
derivative used here inactivates FXIII-A [34] but we cannot rule out a contribution of trang-
lutaminase 2 which is also present in monocytes [35]. However, taken together with the
increase in FXIII-A externalization on monocytes in response to IL-4 and IL-10, these data
suggest that cellular FXIII-A contributes to extracellular cross-linking reactions.
Monocytes activated by different agonists give rise to different phenotypes and func-
tions [36]. IL-4 results in a reparative phenotype, IL-10 activation leads to development
of immunosuppressive function whereas LPS drives proinflammatory responses. IL-10 is
increased in the vein wall upon induction of thrombosis and helps to dampen inflamma-
tion [37]. Furthermore, recombinant IL-10 inhibits thrombosis in vivo [37] and contrary to
this, individuals with depressed levels of IL-10 show enhanced levels of arterial and venous
thrombosis [38,39]. These effects could be explained by the ability of IL-10 to directly atten-
uate monocyte tissue factor exposure and modulate fibrinolysis [40]. Monocyte-derived
macrophages within experimental thrombi are primarily of the M2 phenotype [41]. The in-
crease in FXIII-A externalization on monocytes of a reparative phenotype is perhaps not
surprising given the now well-documented role of this transglutaminase in wound heal-
ing [42]. FXIII-deficient patients and FXIII-A-deficient mice display delayed wound healing,
which can be corrected with infusion of FXIII-A [43,44]. High levels of FXIII activity have
been observed in healing infarct tissue and deficient mice demonstrate increased cardiac
rupture, which is rescued by infusion of FXIII-A2B2 [45]. Promotion of wound healing of
surgical wounds in patients by direct application of FXIII has also been described [1,46].
Interestingly, thrombin treatment of monocytes does not augment exposure of FXIII-A [18],
suggesting these cells may contribute to hemostasis in a situation where there is also an
increase in the type 2 immune response, for example, in a wound-healing capacity.
This study is the first to address the direct impact of monocyte-derived FXIII-A on
thrombus stability. We have shown that IL-4 or IL-10 stimulation of monocytes promotes ex-
ternalization and accumulation of active FXIII-A on the cell membrane that enhances throm-
bus stability for fibrinolytic degradation. Monocytes of reparative/immunosuppressive
phenotype may therefore function to stabilize thrombi at sites of inflammation thereby
promoting efficient wound healing. These observations on external cross-linking functions
of monocyte-derived FXIII-A are particularly relevant in light of the mounting evidence
that monocytes are players in venous thrombus formation [15] and can be recruited during
venous thrombus formation [16]. In addition to FXIII-A, monocytes harbor procoagulant
tissue factor [15] and profibrinolytic proteins, specifically uPA [47]. Given this reservoir of
hemostatic proteins which could function in thrombus initiation, stabilization, resolution
and wound healing, further work is imperative to delineate the complex role of these
inflammatory cells in venous thrombosis.
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4. Materials and Methods
4.1. Blood Collection and Preparation of Serum
Ethical approval for blood sampling from consenting healthy volunteers was granted
by the Ethics Review Board of the College of Life Science & Medicine, University of
Aberdeen, in accordance with the declaration of Helsinki. Blood samples were taken
by venepuncture and collected into EDTA vacuettes (Greiner Bio-one Ltd., Stonehouse,
UK) for monocyte isolate or into serum separating blood tubes. Serum was prepared by
incubating at 37 ◦C for 30 min and then at 4 ◦C for 30 min. Tubes were centrifuged at
400× g for 20 min. Serum was collected and de-complemented by incubating at 56 ◦C for
30 min before storing at −18 ◦C. For preparation of platelet-poor plasma, blood was drawn
into 3.2% sodium citrate and spun at 1860× g for 30 min at 4 ◦C. Plasma from at least
20 donors was pooled, aliquoted and stored at −70 ◦C for pooled normal plasma (PNP).
4.2. Isolation of Peripheral Blood Mononuclear Cells
Peripheral Blood Mononuclear Cells (PBMCs) were isolated by density gradient
centrifugation using Lymphoprep (Axis-Shield, Dundee, UK) according to manufacturers’
recommendation. Monocytes were positively selected from PBMCs by magnetic-activated
cell sorting (MACS), using anti-CD14+ MicroBeads (Miltenyi Biotec, Surrey, UK).
4.3. Culture and Stimulation of Isolated Monocytes and THP-1
Isolated human monocytes were allowed to rest for 24 h prior to stimulation in
RPMI 1640 Medium (Gibco, ThermoFisher, Paisley, UK) supplemented with 1% L-glutamine
(Gibco), 1% penicillin/streptomycin (Gibco) and 5% de-complemented human serum.
THP-1 cell line (Sigma–Aldrich, St-Louis, MO, USA), a human monocytic cell line
derived from monocytic leukemia patients, was cultured in RPMI 1640 supplemented with
L-glutamine, 10% fetal calf serum (FCS; VWR International Ltd, Lutterworth, UK) and
1% penicillin and streptomycin (PenStrep) at 37 ◦C with 5% CO2.
THP-1 or monocytes were seeded into 24-well plates (6 × 105cells/mL) in RPMI 1640
and were left untreated or were treated with 20 ng/mL interleukin-4 (IL-4; Fischer Scien-
tific, Loughborough, UK), 20 ng/mL interleukin-10 (IL-10; PeproTech, London, UK) or
100 ng/mL lipopolysaccharide (LPS; Sigma–Aldrich) for 24 h or in some experiments for
the time of 48 h. Cells were washed following stimulation to ensure serum was removed.
4.4. Preparation of THP-1 Cell Fractions
THP-1 cells (6 × 105cells/mL) were subjected to centrifugation of cells at 2500× g
for 5 min to collect the supernatant. The cells were washed twice in cold sterile PBS
(Sigma–Aldrich) and centrifuged at 2500× g for 5 min before resuspending in RIPA buffer
(ThermoFisher) and incubating for 15 min on ice. The lysate was centrifuged at 14,000× g
for 15 min and the supernatant was collected as cytoplasm fractions. The precipitate was
resuspended to the original volume in RIPA buffer reflecting the membrane fraction.
4.5. Flow Cytometry
Stimulated monocytes/THP-1 cells were re-suspended in Hanks balanced salt solution
(HBSS) containing 1% BSA (bovine serum albumin) for 1 h at ambient temperature and
incubated with a FITC labelled anti-FXIII-A antibody (40 µg/mL; Zedira GmBH, Darmstadt,
Germany) or the fluorescent amine donor substrate, TAMRA (N-tetramethylrhodaminylca-
daverine; 40 µg/mL; Zedira) with 0.5 mM CaCl2 for 30 min. Cells were then washed by
centrifuging at 300× g in HBSS twice to remove unbound antibody or substrate. FXIII-A
exposure and activity were detected using an LSR II flow cytometer (Becton Dickinson,
Franklin Lakes, NJ, USA). A minimum of 10,000 events were collected. Data analysis was
performed using FlowJo software (Tree Star Inc, BD, Ashland, OR, USA.) and gated based
on a forward and side scatter gate.
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4.6. Fluorescent Confocal Microscopy
Cells were harvested, centrifuged and re-suspended in Hanks balanced salt solution
(HBSS) containing 1% BSA (bovine serum albumin) for 1 h at ambient temperature. An FITC
labelled polyclonal anti-FXIII-A antibody or TAMRA (40 µg/mL) supplemented with
0.5 mM CaCl2 was added for 30 min before washing twice with HBSS. Cells were added to
Ibidi µ-slide VI0.4 chambers and imaged using brightfield and at excitation wavelengths of
488 nm or 547 nm on a Zeiss LSM 880 confocal microscope with a 63 × 1.40 oil immersion
objective or with a 60 × objective on an EVOS fluorescence microscope and analyzed by
using Zen 2012 software.
4.7. FXIII Activity Assay
FXIII activity in unstimulated and stimulated THP-1 cells was quantified using an in-
house activity assay as previously described [12,21]. Briefly, human fibronectin (5 µg/well)
was used to coat a 96-well plate (CoStar, Corning, MA, USA). Recombinant FXIII-A (Tret-
ten; Novo Nordisk A/S, Denmark) and samples were preactivated with 1 U/mL bovine
thrombin (Sigma Aldrich) for 5 min at 37 ◦C and residual thrombin was neutralized by
the addition of 20 U/mL hirudin (Sigma Aldrich). A standard curve was prepared by
diluting standard FXIIIa in 0.1 M Tris, 1 mM Dithiothreitol (pH 7.4). The transglutaminase
reaction, in 0.1 M Tris, 1 mM Dithiothreitol, 1 % BSA, 0.5 mM 5-(biotinamido) pentylamine
(ThermoFisher) and 5 mM CaCl2, was stopped after 2 h at 37 ◦C by the addition of 2 mM
EDTA in 0.1 M Tris (pH 7.4). Plates were then washed and blocked with 0.5 % (w/v)
milk powder for 30 min at 37 ◦C and incorporated biotinylated amine was detected using
para-nitrophenyl phosphate substrate. The absorbance was read at 405 nm (reference filter
690 nm) on a Labsystems iEMS 1401 spectrophotometer (Labsystems Oy, Helsinki, Finland).
4.8. Thrombus Formation, Lysis and Fixation
Model thrombi were formed as described [12]. Briefly, PNP or factor XIII-deficient
plasma (FXIII–/–; Affinity Biologicals, Ancaster, Canada) containing 45 µg/mL FITC
(fluorescein isothiocyanate) labelled fibrinogen was re-calcified with CaCl2 (10.9 mM).
Stimulated monocytes were included at 3 × 105 cells/mL. In some experiments, 1 mM
non-reversible inhibitor of TG (1,3-dimethyl-2-[(2-oxopropyl) thio] imidazolium chloride;
produced in house) was included. Thrombi were extracted from the loops and bathed in
1 µg/mL tissue plasminogen activator (tPA; Genetech, CA, USA). Samples were taken at
30-min intervals for 4 h. Fluorescence was read (excitation 485 nm and emission 528 nm)
on a Biotek Instruments Fluorometer (Agilent Technologies LDA UK Ltd, Harwell, UK).
Alternatively, thrombi, formed in the absence of FITC-fibrinogen, were fixed in 10% for-
malin for 24 h before embedding in wax and sectioning.
4.9. Immunohistochemistry
Sections were deparaffinized and dehydrated followed by microwaving in citrate
buffer (pH 6.0) for antigen retrieval and endogenous peroxidase activity quenched with
3% (vol/vol) H2O2 in methanol. Sections were stained with polyclonal rabbit, anti-human
antibodies for fibrinogen (Agilent Technologies) and FXIII-A (Abcam, Cambridge, UK) and
subsequently with biotin-conjugated mouse secondary antibody (Vector laboratories, CA,
USA). Avidin/Biotin ABC enzyme complex was applied, and slides were incubated with
ImmPACT DAB substrate (Vector laboratories). Slides were counterstained with Mayer’s
hematoxylin and nuclei blued with Scots tap water. Sections were imaged using a Zeiss Z1
Axioscan slide scanner at ×5 and ×20 magnification.
4.10. Data Analysis
Rates of lysis (FU/min−1) for model thrombi were determined by best fit of the slope
to a centered second-order polynomial quadratic in GraphPad Prism 5.04 and used to
calculate fold differences in lysis. Statistical analysis was performed on lysis data using one-
way repeated measurement ANOVA (analysis of variance) followed by Dunnett’s multiple
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comparison post hoc test in GraphPad Prism 5.04 (CA, USA). P-values less than 0.05 were
taken as statistically significant, and values are given as the mean ± SEM (standard error
of mean).
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